Kevin Franks

Consultant Clinical Oncologist/Associate Professor

Leeds Teaching Hospitals NHS Trust

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kevin Franks is an Associate Professor and Consultant Clinical Oncologist at Leeds Teaching Hospitals NHS Trust in the UK. His research focuses on lung cancer treatment modalities, including stereotactic ablative radiotherapy (SABR) and its clinical implications, as well as radiation pneumonitis management. He has contributed significantly to the understanding of cardiac toxicity related to thoracic radiotherapy and has published extensively on shared decision-making in cancer care.

Articles (11)

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Patricia (Trish) Holch

Reader in Applied Health Psychology

Leeds Beckett University

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin Franks

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study

Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study

The Impact of Intra-thoracic Anatomical Changes upon the Delivery of Lung Stereotactic Ablative Radiotherapy.

Shared decision-making in early stage non-small cell lung cancer: A systematic review.

An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer.

Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.

Patients' views of routine quality of life assessment following a diagnosis of early-stage non-small cell lung cancer.

Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.

Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.

Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.

SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.

Collaborators (1)

Patricia (Trish) Holch

Make your next move.